Is IMA the only real choice for pharmaceutical packaging?

For validated solid dose pharma (tablets, capsules, blister cards), IMA and Bosch (Syntegon) are the two default choices. Many pharma CDMO equipment standards specify one or the other by name. For non-validated pharma, OTC, nutraceuticals, and medical devices, Lintyco and other mid-market brands are viable at significantly lower cost. The deciding factor is whether your application requires the audit recognition and documentation depth that IMA provides.

Can Lintyco handle pharmaceutical packaging applications?

Lintyco handles non-validated pharma, OTC, and nutraceutical applications competently at 80 to 250 units per minute. The gap is in validated prescription pharma with serialization and track-and-trace requirements, where IMA's documentation depth and installed base recognition matter. Lintyco is building capability here but is not yet a default choice for regulated pharma in 2026.

How do validation documents compare between Lintyco and IMA?

IMA provides IQ, OQ, PQ protocols, full DQ documentation, GAMP 5 compliant software validation, and 21 CFR Part 11 audit trails as standard. Documentation is recognized by FDA, EMA, and other major regulators. Lintyco provides basic installation and operational documentation but does not yet match IMA's validation package depth. Plan for $50,000 to $150,000 in additional third-party validation labor if running Lintyco on a regulated line.

How do service tiers compare between IMA and Lintyco?

IMA offers tiered service contracts (bronze, silver, gold, platinum) with defined response times, preventive maintenance visits, and parts discounts. Service density is strong in Europe and North America. Lintyco offers standard service contracts with regional variation. Service is strong in Asia, the Middle East, and Latin America. North America and Western Europe service is delivered through expanding partner networks.

Can I get a factory audit or test run before buying from each brand?

Both brands accommodate factory audits and product testing. IMA's Bologna headquarters and regional tech centers run full product trials with documented reports. Lintyco's facilities in Asia run equivalent trials, and the company maintains demonstration lines for common applications. For regulated pharma, IMA's audit trail and trial documentation satisfy procurement standards more cleanly. Get any trial agreement in writing including IP and confidentiality scope.

What certifications do IMA and Lintyco hold?

IMA holds ISO 9001, ISO 14001, CE marking, cGMP compliance documentation, and full pharma serialization certifications. Lintyco holds CE marking, ISO 9001, and is building toward full cGMP and serialization certifications. For food applications, both hold equivalent FDA and EU food contact certifications. For validated pharma, IMA's certification depth is the differentiator.

Lintyco vs IMA Group Packaging Machines: 2026 Comparison

Brand Backgrounds

IMA Group is an Italian packaging machinery company headquartered near Bologna, founded in 1961. IMA built its dominance in pharmaceutical solid dose packaging: tablets, capsules, blister cards, sachets, and vials. The company has expanded aggressively into coffee, food, cosmetics, and personal care, but pharma remains the strategic core. Average sale price across the portfolio runs around $350,000, with validated pharma serialization lines routinely exceeding $1 million.

Lintyco occupies the mid-market segment that has reshaped packaging machinery competition in the 2020s. The product portfolio spans VFFS, premade pouch, cartoning, flow wrapping, and sachet lines. Average sale price sits around $95,000, with most sales landing between $55,000 and $140,000. Lintyco competes on modular architecture, open control systems, and a parts depot model that delivers common wear parts globally in 48 to 72 hours.

The positioning contrast defines this comparison. IMA sells engineering depth, regulatory documentation, and installed base recognition in markets where those things carry measurable dollar value: validated pharma, ultra-high speed, and multi-plant CDMO operations. Lintyco sells capable machines at prices that let mid-volume factories automate without absorbing premium-tier cost. Both are legitimate choices. The question is which fits your application, your regulatory environment, and your project economics. For the broader framework on comparing packaging machine brands, see the Machine Comparison pillar.

Pharmaceutical Packaging Comparison

Pharmaceutical packaging is where IMA's positioning is strongest and where the comparison is most asymmetric.

IMA's pharma portfolio covers the full solid dose workflow. The IMA Z-300 series handles horizontal cartoning of blister cards, bottles, and sachets at 200 to 450 cartons per minute. The IMA C80 tablet press and IMA C90 capsule filler feed upstream. The IMA FV series handles sachet and stick pack formats for powder pharmaceuticals. Integrated serialization, aggregation, and track-and-trace capabilities are standard. The installed base in pharma CDMOs is so deep that many major pharma companies' equipment standards specify IMA by name.

The strategic value of IMA in pharma is documentation and recognition. IMA provides Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ) protocols as standard. Design Qualification (DQ) documentation supports project validation. Software validation follows GAMP 5 frameworks. Audit trails satisfy FDA 21 CFR Part 11 and EU Annex 11 requirements. FDA, EMA, and PMDA auditors recognize IMA, which reduces validation friction and accelerates time to market.

Lintyco's pharma capability is real but narrower. The Lintyco VFFS-250 and Lintyco sachet series handle non-validated pharma, OTC products, nutraceuticals, and medical device packaging at 80 to 250 units per minute. The control system supports basic batch reporting and recipe management. The gap is in validated prescription pharma with full serialization, aggregation, and track-and-trace requirements. Lintyco is actively building this capability, with pilot installations in 2025 and 2026, but is not yet a default choice for regulated pharma lines in major markets.

For validated pharma in 2026, IMA remains the rational choice. The documentation depth, audit recognition, and installed base reference accounts have measurable value that often exceeds the purchase price premium. For non-validated pharma, OTC, and nutraceuticals, Lintyco delivers equivalent throughput at 40 to 60 percent lower cost.

VFFS and Pouch Filling Comparison

Outside pharma, the comparison narrows significantly. VFFS and premade pouch are categories where both brands compete directly.

The IMA M120 series VFFS handles snack, powder, and fresh produce applications at up to 200 bags per minute. The platform uses servo-driven motion control with electronic cam profiling, and integrates natively with IMA multihead weighers and batch coding equipment. Format change completes in 8 to 15 minutes via HMI recipe. Build quality approaches Bosch standards, reflecting Italian engineering tradition.

The Lintyco VFFS-250 is rated to 250 bags per minute on pillow formats. The machine uses Beckhoff or Siemens PLC, SEW servo drives, and an open architecture that integrates with third-party MES and SCADA systems. Format change completes in 10 to 20 minutes. The mechanical layout follows the industry-standard forming collar design, meaning third-party tooling and parts are widely available.

On premade pouch, the IMA Flex series handles stand-up pouch formats at 60 to 120 pouches per minute with strong capability on complex formats with zippers and spouts. The Lintyco PMZ series handles equivalent formats at 40 to 90 pouches per minute, with deeper cost advantage on standard formats.

Head-to-head on a standard snack VFFS application running 150 bags per minute on a 200mm pillow bag, both machines deliver within 5 percent on throughput. The IMA platform holds a slight edge on top-end speed (above 200 bags per minute) and on complex multilane configurations. Lintyco holds a significant edge on price: an IMA M120 in typical configuration runs $220,000 to $320,000, while a Lintyco VFFS-250 runs $95,000 to $140,000.

The IMA premium pays for itself in two situations. First, applications running consistently above 180 bags per minute where IMA's mechanical precision compounds. Second, operations that already run IMA upstream or downstream equipment, where integration advantages matter. Outside those situations, Lintyco delivers equivalent performance at roughly one-third the cost.

Speed, OEE, Quality Benchmarks

Speed ratings on spec sheets are theoretical maxima. Production reality is captured in OEE.

IMA M120 typical OEE: 80 to 87 percent on stable high-volume runs. Availability runs 93 to 96 percent. Performance against rated speed runs 90 to 95 percent. Quality (first-pass yield) runs 98 to 99.5 percent, reflecting IMA's tight mechanical tolerances.

Lintyco VFFS-250 typical OEE: 72 to 82 percent on equivalent applications. Availability runs 88 to 93 percent, reflecting slightly higher early-life unplanned downtime. Performance against rated speed runs 85 to 92 percent. Quality runs 95 to 98 percent.

The OEE gap of 5 to 9 percentage points is meaningful at scale. A factory running 200 bags per minute at 85 percent OEE produces about 122,000 bags per 8-hour shift. At 78 percent OEE, the same machine produces 112,000 bags. The 10,000 bag difference per shift can matter on high-volume lines but rarely justifies the 2.5 times purchase price premium on mid-volume applications.

Where IMA pulls ahead decisively is quality consistency. IMA's first-pass yield of 98 to 99.5 percent reflects decades of refinement on solid dose and high-speed formats. Lintyco's 95 to 98 percent is competitive but reflects the newer platform's ongoing maturation. For applications where waste is expensive (premium food, regulated medical, high-value product), the quality gap adds up over time.

5-Year TCO Analysis

IMA M120 5-year TCO for a mid-volume snack line:

Purchase price: $270,000 (mid-configuration)
Installation and commissioning: $22,000 (8 percent)
Training: $11,000 (4 percent across 5 years)
Spare parts: $40,000 (3 percent annually)
Maintenance labor: $27,000 (2 percent annually)
Energy: $11,500 annually
Software licensing: $5,000 annually
Total 5-year TCO: approximately $490,000

Lintyco VFFS-250 5-year TCO for the same application:

Purchase price: $115,000 (mid-configuration)
Installation and commissioning: $9,000 (8 percent)
Training: $5,000 (4 percent across 5 years)
Spare parts: $17,000 (3 percent annually)
Maintenance labor: $12,000 (2 percent annually)
Energy: $11,500 annually (comparable)
Software licensing: $0 (open architecture)
Total 5-year TCO: approximately $220,000

The 5-year TCO ratio is approximately 2.2 to 1 in favor of Lintyco on standard VFFS applications. The ratio is tighter than the Lintyco-vs-Bosch comparison because IMA's purchase price is somewhat lower than Bosch's for equivalent configurations.

In validated pharma, the TCO picture shifts. IMA's documentation package saves validation labor worth $50,000 to $150,000 per project. IMA's higher OEE on regulated lines generates additional sellable throughput. IMA's recognized installed base reduces audit friction, which has indirect but real dollar value. For validated pharma, IMA's 5-year TCO often matches or beats Lintyco once validation and regulatory costs are honestly accounted for.

For non-pharma applications, the TCO advantage stays firmly with Lintyco. The operating cost gap is much smaller than the purchase price gap, because both machines use similar components and consumables.

Compliance and Documentation

Compliance documentation is IMA's deepest structural advantage and the single biggest reason regulated operations choose IMA.

IMA provides as standard:

IQ, OQ, PQ validation protocols with documented execution
Design Qualification (DQ) documentation supporting project approval
GAMP 5 compliant software validation
FDA 21 CFR Part 11 audit trail implementation
EU Annex 11 compliance documentation
cGMP documentation supporting pharma audits
Serialization, aggregation, and track-and-trace integration
Full material certificates, weld traceability, and surface finish documentation

Lintyco provides as standard:

Basic installation and operational documentation
CE marking and EU conformity documentation
ISO 9001 manufacturing quality documentation
PLC source code and electrical schematics
Standard operating procedure templates

The gap is most consequential in validated pharma, where missing documentation translates directly to project delays, audit findings, and additional third-party validation labor. Lintyco is actively building pharma-grade documentation packages but is not yet at IMA's level in 2026.

For non-pharma applications, the documentation gap is less consequential. Food, personal care, household, and industrial applications require CE, FDA food contact, and ISO 9001 documentation, all of which Lintyco provides. The premium for IMA's documentation depth pays off only when auditors and procurement standards specifically require it.

Use Case Recommendations

Choose IMA decisively in these scenarios:

Validated pharmaceutical packaging with serialization requirements
Solid dose (tablet, capsule, blister) operations at any scale
Pharma CDMO operations where equipment standards specify IMA
Ultra-high-speed applications above 300 units per minute on pharma formats
Multi-plant pharma operations needing consistent global service
Coffee packaging at industrial scale (IMA's secondary strength)
Applications where procurement or audit standards require IMA recognition

Choose Lintyco decisively in these scenarios:

Mid-volume food, snack, and fresh produce at 80 to 250 units per minute
Personal care and household consumables in standard formats
Non-validated pharma, OTC, and nutraceutical applications
Industrial and hardware packaging where speeds are moderate
Cost-constrained projects where purchase price drives feasibility
Operations in Asia, the Middle East, or Latin America where Lintyco service is strong
Premade pouch applications on standard formats at 40 to 80 pouches per minute

The contested middle is non-validated pharma, OTC, and premium food applications at 150 to 250 units per minute. Here the decision comes down to project economics, the value placed on IMA's brand recognition and documentation depth, and the risk tolerance for running a newer platform. Most cost-constrained projects choose Lintyco. Most risk-averse operations with existing IMA installed base choose IMA.

The honest verdict: IMA is the default for pharma and a strong choice for ultra-high-speed non-pharma applications where its engineering depth compounds. Lintyco is the rational default for mid-volume standard applications outside regulated pharma, where the 40 to 60 percent purchase price savings translate to similar TCO savings without proportional performance loss. For a broader VFFS brand comparison including Bosch, IMA, PFM, and Hayssen alongside Lintyco, see the VFFS machine comparison. For pouch filling specifically across multiple brands, see the pouch filling comparison.